Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-CSF3R, F-627 Vector   (CAT#: GTVCR-WQ1176MR)

This product GTVCR-WQ1176MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting CSF3R. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Homo sapiens
RefSeq NM_000760.4
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-CSF3R, F-627 Vector (GTVCR-WQ1176MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2033MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD248, MORAb-004 Vector Vector MORAb-004
GTVCR-WQ2407MR IVTScrip™ pT7-VEE-mRNA-Anti-IFNA1, RhuMAB IFNalpha Vector Vector RhuMAB IFNalpha
GTVCR-WQ814MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD4, BT-061 Vector Vector BT-061
GTVCR-WQ2513MR IVTScrip™ pSP6-VEE-mRNA-Anti-CSF1R, SNDX-6352 Vector Vector SNDX-6352
GTVCR-WQ2181MR IVTScrip™ pSP6-VEE-mRNA-Anti-IFNAR, Peg-IFNA2 R23 Vector Vector Peg-IFNA2 R23
GTVCR-WQ2280MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFSF4, R4930 Vector Vector R4930
GTVCR-WQ249MR IVTScrip™ pSP6-VEE-mRNA-Anti-Aβ15-42, ACC-001 Vector Vector ACC-001
GTVCR-WQ1274MR IVTScrip™ pSP6-VEE-mRNA-Anti-CSF3R, G-CSF Vector Vector G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW